Statements (51)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
biotechnology company
|
| gptkbp:awards |
Best Startup Award 2021
Innovation in Medicine Award 2022 |
| gptkbp:CEO |
gptkb:Dr._John_Smith
|
| gptkbp:clinicalTrials |
gptkb:California
gptkb:New_York gptkb:Texas 150 200 300 ongoing positive completed pending Phase 2 favorable promising |
| gptkbp:collaboratedWith |
Pharmaceutical Company X
Research_Institute_Y |
| gptkbp:employeeCount |
50
|
| gptkbp:focusArea |
therapeutics for neurological disorders
|
| gptkbp:foundedIn |
2020
|
| gptkbp:funding |
Series A
|
| gptkbp:futurePlans |
increase research funding
expand product line enter new markets |
| gptkbp:headquarters |
gptkb:San_Francisco,_California
|
| https://www.w3.org/2000/01/rdf-schema#label |
Omid Therapeutics
|
| gptkbp:investmentFocus |
gptkb:Venture_Capital_Firm_B
Venture_Capital_Firm_A |
| gptkbp:keyFigures |
OMD-101
|
| gptkbp:market |
gptkb:Asia
gptkb:North_America Europe |
| gptkbp:partnerships |
gptkb:University_of_California
|
| gptkbp:patentCitation |
OMD-101 patent
OMD-102 patent |
| gptkbp:profession |
$50 million
|
| gptkbp:regulatoryCompliance |
gptkb:FDA
EMA |
| gptkbp:researchFocus |
neurodegenerative diseases
mood disorders cognitive disorders |
| gptkbp:researchInterest |
gptkb:National_Institutes_of_Health
|
| gptkbp:socialResponsibility |
improve patient outcomes
advance medical research support healthcare professionals |
| gptkbp:supports |
clinical trials
|
| gptkbp:targets |
Alzheimer's disease
Parkinson's disease |
| gptkbp:website |
www.omidtherapeutics.com
|